gBRCAm HER2- breast cancer
Oncology · 2019–2019
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| talazoparib Treatment of patients with germline breast cancer susceptibility gene mutated (gBRCAm) human epidermal growth factor receptor negative (HER2-) locally advanced… | Nov 2019 | Not recommended | input received Breast Cancer Network Australia |
Who spoke
Breast Cancer Network Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.